Investor Presentaiton

GUARDANT 360 Response Overcomes limitations of existing tools used to measure treatment response INVESTOR 20 DAY 23 Accelerated insight into treatment response Measure ctDNA change and drug efficacy earlier than standard imaging Accelerates clinical trials and drug development Advantages of a tissue-free approach Overcome logistical challenges of tissue- informed approaches, such as tissue insufficiency, increased time due to procurement, and invasive procedures Improved sensitivity and precision with methylation Guardant360 Response on the Smart Liquid Biopsy platform will provide even deeper tumor sensing and higher precision Real-time clinical decision making Rapidly assess drug efficacy, enabling fast-fail drug development model Consider alternate treatments or dosing for non-responders GUARDANT™ 51

View entire presentation